Desvenlafaxine Tablet, Extended Release
Product Images NDC 63629-7525

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63629-7525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A forest plot chart illustrating the geometric mean ratio (90% confidence interval) of Cmax and AUC pharmacokinetic parameters for Desvenlafaxine. It compares changes relative to reference values across groups with varying renal impairment severities, hepatic impairment severities, and population subgroups by gender and age (65 to >75 years). ESRD refers to End Stage Renal Disease.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A pharmacokinetic chart showing the geometric mean ratio with 90% confidence intervals for the effect of the CYP3A4 inhibitor ketoconazole on Desvenlafaxine. The graph plots values for Cmax and AUC against a reference baseline, illustrating relative changes in drug concentration parameters.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A chart showing geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for various interacting drugs with Desvenlafaxine at different doses. The drugs listed include desipramine, midazolam, tamoxifen, and aripiprazole. The data compares changes in these parameters relative to reference values, indicating interaction effects on metabolism mediated by CYP2D6 and CYP3A4 enzymes.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A Kaplan-Meier curve chart depicting the estimated proportion of patients with relapse (%) over time in days from randomization. It compares relapse rates between Desvenlafaxine Extended-Release Tablets 50 mg and placebo, showing lower relapse proportions in the Desvenlafaxine group throughout the duration up to approximately 200 days.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A Kaplan-Meier plot depicting the estimated proportion of patients experiencing relapse (%) over time in days from randomization. The chart compares two groups: Desvenlafaxine Extended-Release Tablets and Placebo, showing relapse proportion on the vertical axis and time on the horizontal axis.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure of desvenlafaxine succinate dihydrate, depicting the molecular arrangement of atoms including hydroxyl groups, amine groups, carboxyl groups, and associated water molecule.*

FDA Label Image

Label Image (Lbl636297525)

Label for Desvenlafaxine ER 50 mg tablets, extended-release oral tablets packaged by Bryant Ranch Prepack. The label compares this product to Pristiq 50 mg tablet by Alembic Pharmaceuticals Limited. It includes storage instructions at 20-25°C (68-77°F), a lot number, and a barcode. The label also states the product is RX only and has an NDC of 63629-7525.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.